
Published
17 June 2011 | By Genevac
Nerviano Medical Sciences (NMS) is a new company created following the spin-off by Pfizer of their R&D centre in Nerviano (Milan, Italy). Through its Preclinical Development (PCD) unit, NMS specialises in toxicology, drug metabolism and pharmacokinetics services to pharmaceutical and biotechnology companies. These PCD capabilities are used to support the selection of candidate drugs, predict clinical outcomes from preclinical data (in silico, in vitro, in vivo) and then perform preclinical studies to reduce the attrition rate in the clinic and accelerate the whole drug development process.
As a registered user of PBR you can skip the majority of this form. Registration is FREE so register now or log in if you're already a member.
Fill In Details
By clicking the 'download white paper' button you agree to pass your details as shown to the white paper advertiser. The enquirer also permits the advertiser to follow up the enquiry by phone or email. PBR is in no way responsible for further communication between parties.
Fields marked * are compulsory
Fields marked * are compulsory